Gliomas Clinical Trial
Official title:
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults
To learn if the study drug, ulixertinib, can cross over the blood-brain barrier in patients with recurrent brain tumors
Primary Objective: 1. To evaluate the ability of ulixertinib to penetrate the BBB in patients with recurrent MAPK-activated LGG (ulixertinib tumor concentration, tumor/plasma ratio and tumor/cerebrospinal fluid (CSF) ratio) Secondary Objectives: 1. To assess anti-tumor activity of ulixertinib for patients with recurrent lower grade MAPK-activated gliomas after surgical resection based on: 1. Median progression-free-survival (mPFS) 2. Objective response rate (ORR) at 12 months 3. Disease control rate (DCR) at 12 months 4. Duration of response (DOR) 5. Time to response (TTR) 6. Time to next intervention 2. To assess safety and tolerability of ulixertinib in MAPK-activated LGG ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03952598 -
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
|
N/A | |
| Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
| Terminated |
NCT01251913 -
A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes
|
||
| Withdrawn |
NCT01961934 -
C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03557359 -
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
|
Phase 2 | |
| Recruiting |
NCT01655927 -
Efficacy of Tranexamic Acid in Brain Tumor Resections
|
Phase 3 | |
| Completed |
NCT01144247 -
Cellular Immunotherapy Study for Brain Cancer
|
Phase 1 | |
| Completed |
NCT01225003 -
Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas
|
N/A | |
| Completed |
NCT00967577 -
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
|
Phase 1 | |
| Terminated |
NCT01517776 -
Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents
|
Phase 2 | |
| Completed |
NCT00832598 -
[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors
|
N/A | |
| Completed |
NCT00589706 -
A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
|
Phase 2 | |
| Completed |
NCT03154996 -
Chronic Convection Enhanced Delivery of Topotecan
|
Phase 1 | |
| Withdrawn |
NCT05054400 -
Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR
|
Early Phase 1 | |
| Recruiting |
NCT03091270 -
ZOOMit-fMRI Identifies Motor Functional Cortex
|
||
| Completed |
NCT00200161 -
Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
|
Phase 2 | |
| Terminated |
NCT02332889 -
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
|
Phase 1/Phase 2 |